Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Care Plans, Education Improve Long-term Quality of Life

June 17, 2023
By Julie M. Vose, MD, MBA
Publication
Article
OncologyONCOLOGY Vol 37, Issue 6
Volume 37
Issue 6
Pages: 233

Co-editor-in-Chief Julie M. Vose, MD, MBA, writes about the optimal ways to manage short- and long-term toxicities associated with cancer.

With 1 in 3 individuals receiving a cancer diagnosis sometime during their lifetime, we all are likely to experience cancer ourselves or to have a relative or close friend with cancer. Fortunately, there have been vast improvements in treatments and care for patients with cancer. But with those successful treatments often come short- and long-term toxicities that must be managed.

In 2006, the Institute of Medicine and the National Academies established a committee to examine the range of medical and psychosocial issues faced by cancer survivors needed to improve their health care and quality of life.1 The committee set out 10 recommendations that fit into 4 broad categories: prevention, surveillance, intervention, and coordination.1 One big part of the recommendations was that each patient who had received cancer therapy should receive a survivorship care plan written by the team providing the cancer care. These plans should be developed systematically and on evidence-based clinical practice guidelines, the committee noted. Many of these plans have been developed as a shared-care model in which specialists work collaboratively with primary care providers. This model is likely the most successful because much of the cancer survivor’s health care is provided by their primary care network.

In addition to evaluations for cancer recurrence, services are needed for cancer screenings and evaluation of secondary effects such as organ dysfunction or secondary malignancies. Educating patients on primary and secondary prevention services, such as smoking cessation or regular cancer screening tests, is an important part of cancer survivorship. Cancer survivors also should receive additional lifestyle education such as how to maintain a healthy weight or increase activity. Some vital issues that are difficult to address include the need for services from psychologists or social workers. Even though the American Disabilities Act, has offered cancer survivors some protections from discriminatory practices, there are still many cases of health-related discrimination. Survivorship is an essential part of cancer care and benefits should be available based on evidence-based medicine.

The written survivorship care plan that is done at the end of active treatment for a patient with cancer does not guarantee a smooth transition or adequate education. It is an outline or road map for the patient, family, and primary care physician to follow. It should be a short, concise document that contains relevant information but does not overwhelm the patient or family. A specialty team trained to deliver the survivorship care plan is particularly beneficial in assisting patients with the transition.

A follow-up national cancer policy forum workshop in 2017 examined the implementation of the 2006 recommendations.2 Although many of the original recommendations have been implemented, some are less universal, such as protections from health-related discriminatory practices.2 Investing in research to improve cancer survivorship also was called out in the recommendations, particularly research on mechanisms of the late effects, prevalence of the risk of late effects, and interventions to improve the quality of life of all cancer survivors, their families, and caregivers. As a community of hematologists/oncologists, we owe it to our patients to not only improve our anticancer therapies but also to decrease the short- and long-term effects of the therapies we recommend for our patients.

References

  1. Institute of Medicine and National Research Council. From Cancer Patient to Cancer Survivor: Lost in Transition. The National Academies Press; 2005.
  2. Kline RM, Arora NK, Bradley CJ, et al. Long-term survivorship care after cancer treatment - summary of a 2017 National Cancer Policy Forum workshop. J Natl Cancer Inst. 2018;110(12):1300- 1310. doi:10.1093/jnci/djy176
Download Issue PDFDownload PDF
Articles in this issue

Erdafitinib in the Treatment of Metastatic Urothelial Carcinoma
Erdafitinib in the Treatment of Metastatic Urothelial Carcinoma
Squamous Cell Carcinoma of the Kidney: A Large Case Series
Squamous Cell Carcinoma of the Kidney: A Large Case Series
Erdafitinib’s Road to Approval and Use in Urothelial Carcinoma
Erdafitinib’s Road to Approval and Use in Urothelial Carcinoma
Researchers Seek More Treatment Options for Gastrointestinal Cancer
Researchers Seek More Treatment Options for Gastrointestinal Cancer
Care Plans, Education Improve Long-term Quality of Life
Care Plans, Education Improve Long-term Quality of Life
Recent Videos
According to John Henson, MD, “What we need are better treatments to control the [brain] tumor once it’s detected.”
First-degree relatives of patients who passed away from pancreatic cancer should be genetically tested to identify their risk for the disease.
Destigmatizing cancer care for incarcerated patients may help ensure that they feel supported both in their treatment and their humanity.
A lower percentage of patients who were released within 1 year of incarceration received guideline-concurrent care vs incarcerated patients.
A collaboration between the Connecticut Departments of Health and Corrections and the COPPER Center aimed to improve outcomes among incarcerated patients.
Computational models help researchers anticipate how ADCs may behave in later lines of development, while they are still in the early stages.
ADC payloads with high levels of potency can sometimes lead to higher levels of toxicity, which can eliminate the therapeutic window for patients with cancer.
According to Greg Thurber, PhD, target-mediated uptake is the biggest driver of efficacy for antibody-drug conjugates as a cancer treatment.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to expect at the 43rd Annual Chemotherapy Foundation Symposium, such as new chemotherapeutics and targeted therapies.
In neuroendocrine tumor management, patients with insulinoma may be at risk of severe hypoglycemia following receipt of GLP-1 receptor agonists.
Related Content
Advertisement

PAS-004 was deemed safe and tolerable when given in 37 mg capsules, so the trial will proceed to administer the agent in 45 mg capsules.

Cohort 7 of Novel MEK Inhibitor Trial Completed for MAPK Pathway-Driven Tumors

Tim Cortese
November 25th 2025
Article

PAS-004 was deemed safe and tolerable when given in 37 mg capsules, so the trial will proceed to administer the agent in 45 mg capsules.


Decision-Making Capacity: The Ethical Core of Patient-Centered Oncology

Decision-Making Capacity: The Ethical Core of Patient-Centered Oncology

Daniel C. McFarland, DO;Louis P. Voigt, MD;Yesne Alici, MD
November 24th 2025
Podcast

Daniel C. McFarland, DO, is joined by Louis P. Voigt, MD, and Yesne Alici, MD, who focused on decision-making capacity and patient-centered care.


Novel Agent Yields Promising Results in MAPK-Associated Solid Tumors

Novel Agent Yields Promising Results in MAPK-Associated Solid Tumors

Ariana Pelosci
November 21st 2025
Article

Partial responses and stable disease were observed with PAS-004 in patients with advanced solid tumors harboring RAS, NF1, or RAF mutations.


Experts discussed supportive care and why it should be integrated into standard oncology care.

How Supportive Care Methods Can Improve Oncology Outcomes

Declan Walsh, MD;Denise B. Reynolds, RD;Adam Friedman, MD, FAAD;Daniel C. McFarland, DO;Michelle Fingeret, PhD;Christian J. Nelson, PhD;William S. Breitbart, MD
November 10th 2025
Podcast

Experts discussed supportive care and why it should be integrated into standard oncology care.


The regulatory decision regarding the subcutaneous pembrolizumab formulation is based on results from the phase 3 3475A-D77 trial.

EU Approves Subcutaneous Pembrolizumab in All Approved Indications

Roman Fabbricatore
November 19th 2025
Article

The regulatory decision regarding the subcutaneous pembrolizumab formulation is based on results from the phase 3 3475A-D77 trial.


Results from the KOMET trial led to the approval of selumetinib in adults with NF1 symptomatic, inoperable plexiform neurofibromas.

FDA OKs Selumetinib in NF1 Symptomatic, Inoperable Plexiform Neurofibromas

Ariana Pelosci
November 19th 2025
Article

Results from the KOMET trial led to the approval of selumetinib in adults with NF1 symptomatic, inoperable plexiform neurofibromas.

Related Content
Advertisement

PAS-004 was deemed safe and tolerable when given in 37 mg capsules, so the trial will proceed to administer the agent in 45 mg capsules.

Cohort 7 of Novel MEK Inhibitor Trial Completed for MAPK Pathway-Driven Tumors

Tim Cortese
November 25th 2025
Article

PAS-004 was deemed safe and tolerable when given in 37 mg capsules, so the trial will proceed to administer the agent in 45 mg capsules.


Decision-Making Capacity: The Ethical Core of Patient-Centered Oncology

Decision-Making Capacity: The Ethical Core of Patient-Centered Oncology

Daniel C. McFarland, DO;Louis P. Voigt, MD;Yesne Alici, MD
November 24th 2025
Podcast

Daniel C. McFarland, DO, is joined by Louis P. Voigt, MD, and Yesne Alici, MD, who focused on decision-making capacity and patient-centered care.


Novel Agent Yields Promising Results in MAPK-Associated Solid Tumors

Novel Agent Yields Promising Results in MAPK-Associated Solid Tumors

Ariana Pelosci
November 21st 2025
Article

Partial responses and stable disease were observed with PAS-004 in patients with advanced solid tumors harboring RAS, NF1, or RAF mutations.


Experts discussed supportive care and why it should be integrated into standard oncology care.

How Supportive Care Methods Can Improve Oncology Outcomes

Declan Walsh, MD;Denise B. Reynolds, RD;Adam Friedman, MD, FAAD;Daniel C. McFarland, DO;Michelle Fingeret, PhD;Christian J. Nelson, PhD;William S. Breitbart, MD
November 10th 2025
Podcast

Experts discussed supportive care and why it should be integrated into standard oncology care.


The regulatory decision regarding the subcutaneous pembrolizumab formulation is based on results from the phase 3 3475A-D77 trial.

EU Approves Subcutaneous Pembrolizumab in All Approved Indications

Roman Fabbricatore
November 19th 2025
Article

The regulatory decision regarding the subcutaneous pembrolizumab formulation is based on results from the phase 3 3475A-D77 trial.


Results from the KOMET trial led to the approval of selumetinib in adults with NF1 symptomatic, inoperable plexiform neurofibromas.

FDA OKs Selumetinib in NF1 Symptomatic, Inoperable Plexiform Neurofibromas

Ariana Pelosci
November 19th 2025
Article

Results from the KOMET trial led to the approval of selumetinib in adults with NF1 symptomatic, inoperable plexiform neurofibromas.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.